Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances - Top-Institutions - MDSpire

Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances

  • By

  • Ye Chen

  • Huiyi Liu

  • Peipei Yuan

  • Yongqi Li

  • Changqiong Xu

  • Ran Li

  • Jibing Chen

  • Fasheng Wu

  • June 24, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Shaoguan University
    Shaoguan University

    Shaoguan, Guangdong

    Key Differentiators

    • Oncology

  • #2

    University of California, Los Angeles
    University of California, Los Angeles

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Ludwig Institute, University of California, San Diego
    Ludwig Institute, University of California, San Diego

    La Jolla, California

    Key Differentiators

    • Oncology

  • #5

    University of Texas M.D. Anderson Cancer Center
    University of Texas M.D. Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances

  • by Ye Chen, Huiyi Liu, Peipei Yuan, Yongqi Li, Changqiong Xu, Ran Li, Jibing Chen, Fasheng Wu

  • June 24, 2026

Related Content

Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer

Case Report: Primary hepatic carcinosarcoma with ectopic β-hCG secretion and a paraneoplastic leukemoid reaction mimicking gynecologic and hematologic disease